Application of microRNA in the therapy of ischemic stroke

Stroke is one of the leading causes of death and disability worldwide. The consequences of a stroke are manifested by deep and persistent clinical symptoms, which largely impose a burden on both the patient and society. Current treatments for ischemic stroke have proven to be inadequate, in part bec...

Full description

Saved in:
Bibliographic Details
Main Authors: I. F. Gareev, L. B. Novikova, O. A. Beylerli
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2019-11-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1752
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849250172130820096
author I. F. Gareev
L. B. Novikova
O. A. Beylerli
author_facet I. F. Gareev
L. B. Novikova
O. A. Beylerli
author_sort I. F. Gareev
collection DOAJ
description Stroke is one of the leading causes of death and disability worldwide. The consequences of a stroke are manifested by deep and persistent clinical symptoms, which largely impose a burden on both the patient and society. Current treatments for ischemic stroke have proven to be inadequate, in part because of an incomplete understanding of the cellular and molecular changes that occur during a stroke. Microribonucleic acids (MicroRNAs) are endogenously expressed ribonucleic acid (RNA) of 18-22 nucleotides in length that suppress gene expression at the post-transcriptional level by binding to the 3'-untranslated region of the messenger ribonucleic acids targets. MicroRNAs are involved in virtually all biological processes, including cell proliferation, apoptosis, and cell differentiation, but also play a key role in the pathophysiological processes that contribute to ischemic damage. Moreover, miRNAs can represent not only potential biomarkers, but also become new therapeutic targets in clinical practice, which again confirms the need for their study. Therapy based on miRNA, includes agonists or facial expressions and inhibitors (antagomirs), which accordingly reduces and increases the expression of target genes. In this review, we summarize the current knowledge of fundamental research in the use of microRNAs in the treatment of stroke. The treatment methods, time windows and dosages for the effective delivery of microRNA-based drugs to the central nervous system are discussed. The effects of microRNA therapy on the main pathological mechanisms of stroke, including oxidative stress, inflammation, apoptosis, angiogenesis, neurogenesis, and the safety of the blood-brain barrier are considered.
format Article
id doaj-art-8de2d7139fc545d79422bb718da602dd
institution Kabale University
issn 1728-8800
2619-0125
language Russian
publishDate 2019-11-01
publisher «SILICEA-POLIGRAF» LLC
record_format Article
series Кардиоваскулярная терапия и профилактика
spelling doaj-art-8de2d7139fc545d79422bb718da602dd2025-08-20T03:57:21Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252019-11-01185667310.15829/1728-8800-2019-5-66-731942Application of microRNA in the therapy of ischemic strokeI. F. Gareev0L. B. Novikova1O. A. Beylerli2Bashkir State Medical UniversityBashkir State Medical UniversityBashkir State Medical UniversityStroke is one of the leading causes of death and disability worldwide. The consequences of a stroke are manifested by deep and persistent clinical symptoms, which largely impose a burden on both the patient and society. Current treatments for ischemic stroke have proven to be inadequate, in part because of an incomplete understanding of the cellular and molecular changes that occur during a stroke. Microribonucleic acids (MicroRNAs) are endogenously expressed ribonucleic acid (RNA) of 18-22 nucleotides in length that suppress gene expression at the post-transcriptional level by binding to the 3'-untranslated region of the messenger ribonucleic acids targets. MicroRNAs are involved in virtually all biological processes, including cell proliferation, apoptosis, and cell differentiation, but also play a key role in the pathophysiological processes that contribute to ischemic damage. Moreover, miRNAs can represent not only potential biomarkers, but also become new therapeutic targets in clinical practice, which again confirms the need for their study. Therapy based on miRNA, includes agonists or facial expressions and inhibitors (antagomirs), which accordingly reduces and increases the expression of target genes. In this review, we summarize the current knowledge of fundamental research in the use of microRNAs in the treatment of stroke. The treatment methods, time windows and dosages for the effective delivery of microRNA-based drugs to the central nervous system are discussed. The effects of microRNA therapy on the main pathological mechanisms of stroke, including oxidative stress, inflammation, apoptosis, angiogenesis, neurogenesis, and the safety of the blood-brain barrier are considered.https://cardiovascular.elpub.ru/jour/article/view/1752micrornastrokeexpressiontherapymimicsinhibitors.
spellingShingle I. F. Gareev
L. B. Novikova
O. A. Beylerli
Application of microRNA in the therapy of ischemic stroke
Кардиоваскулярная терапия и профилактика
microrna
stroke
expression
therapy
mimics
inhibitors.
title Application of microRNA in the therapy of ischemic stroke
title_full Application of microRNA in the therapy of ischemic stroke
title_fullStr Application of microRNA in the therapy of ischemic stroke
title_full_unstemmed Application of microRNA in the therapy of ischemic stroke
title_short Application of microRNA in the therapy of ischemic stroke
title_sort application of microrna in the therapy of ischemic stroke
topic microrna
stroke
expression
therapy
mimics
inhibitors.
url https://cardiovascular.elpub.ru/jour/article/view/1752
work_keys_str_mv AT ifgareev applicationofmicrornainthetherapyofischemicstroke
AT lbnovikova applicationofmicrornainthetherapyofischemicstroke
AT oabeylerli applicationofmicrornainthetherapyofischemicstroke